A 2-Dose AERAS-402 Regimen Boosts CD8(+) Polyfunctionality in HIV-Negative, BCG-Vaccinated Recipients

Despite the widespread use of BCG, tuberculosis (TB) remains a global threat. Existing vaccine candidates in clinical trials are designed to replace or boost BCG which does not provide satisfying long-term protection. AERAS-402 is a replication-deficient Ad35 vaccine encoding a fusion protein of the...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Front Immunol
Huvudupphovsmän: Sivakumaran, Dhanasekaran, Blatner, Gretta, Bakken, Rasmus, Hokey, David, Ritz, Christian, Jenum, Synne, Grewal, Harleen M. S.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Frontiers Media S.A. 2021
Ämnen:
Immunology
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8231292/
https://ncbi.nlm.nih.gov/pubmed/34177914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.673532
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk